10 , 13 We observed atrial fibrillation/flutter were slightly more common in patients treated with ibrutinib, but the difference did not reach statistical significance. 4 , 13 Because atrial fibrillation/flutter is known to be a late complication, it is possible that the detection of differences in this event may require longer follow-up.
← all excerpts
Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
1
—
—